Skip to nav Skip to content
  • Cancer Type: Immunotherapy
  • Study Type: Treatment
  • NCT#: NCT05169489
  • Phase: Phase I/II
Learn More
  • Overview

    Study Title:

    A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma


    This is a non-randomized, open label, multi-site Phase 1/2 study. This first-in-human Phase 1/2 Study CRC-403 will evaluate the safety and efficacy of bbT369 in patients with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL). Phase 1 will be a dose escalation, up to a planned four dose levels. After establishing MTD, Phase 2 will enroll patients with B cell NHL in 2 cohorts: CAR T exposed patients (Cohort 1) and CAR T naïve patients (Cohort 2). A long-term follow-up is planned, in which patients who received bbT369 will be followed for up to 15 years after drug product infusion to evaluate for safety and continued efficacy.


    Phase 1: Primary: Determine the maximally tolerated dose (MTD) and/or one or more recommended phase 2 doses (RP2Ds) of bbT369 in subjects with B cell non-Hodgkin s lymphoma (NHL) for use in Phase 2. Evaluate the safety of the RP2D(s). Secondary: Provide preliminary data on the efficacy of bbT369 in subjects with B cell NHL Phase 2: The primary objective of the study is to: Evaluate the efficacy of bbT369 in subjects with B cell NHL The secondary objectives of the study are to: Evaluate the safety of bbT369 in subjects with B cell NHL Evaluate additional efficacy parameters for bbT369 in subjects with B cell NHL Assess health-related quality of life in subjects with B cell NHL after treatment with bbT369

  • Treatments


    Cell Therapy; Therapy (NOS)


    Lymphodepletion (); bbT369 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

  • Inclusion Criteria

      Inclusion Criteria:
    • At least 8 years of age at the time of signing informed consent.
    • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
    • Diagnosis of B-cell NHL according to WHO 2017 classification or WHO 2016 classification where applicable: (1) DLBCL (germinal center B cell [GCB] or activated B cell [ABC] type or not otherwise specified [NOS]) (2) HGBCL (with MYC and BCL2 and/or BCL6 rearrangements or NOS) (3) PMBCL (4) FL 3b (5) DLBCL transformed from FL.
    • Participants must have relapsed or refractory (r/r) B cell NHL after autologous stem cell transplant (ASCT) or at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen. Note: participants with DLBCL transformed from FL must have r/r disease after ASCT or at least 2 prior therapies following transformation irrespective of therapeutic agents.
    • At least 1 FDG-avid lesion per Lugano Classification criteria at time of enrollment.
    • Other criteria may apply
  • Exclusion Criteria

      Exclusion Criteria:
    • Treatment with any investigational cellular therapy prior to enrollment. Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.
    • Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.
    • Residual toxicities or end-organ damage to vital organs from prior therapy that could put a patient at undue risk based on Investigator's assessment. Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.
    • If a patient has received prior anti-CD19 CAR T therapy, development of ≥ Grade 3 CAR T related CRS or ≥ Grade 3 neurotoxicity that in the opinion of the Investigator would cause unacceptable risk of toxicity to the patient upon treatment with bbT369.
    • Primary central nervous system (CNS) lymphoma or a history or presence of clinically relevant CNS pathology.
    • Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.
    • Treatment with any prior anti-CD79a therapy.
    • Previous history of an allogeneic bone marrow transplantation. Autologous stem cell transplantation (ASCT) is permitted.
    • Additional exclusions may apply

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trial Search